GlassScriptPhysician profile
Laura Caroline Jones
NPI 1770081960
$2,219.71
in general payments reported to CMS, 2019-2025
35 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $645 · 2022: $720 · 2023: $564 · 2024: $136 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $331.50 | 2021-2024 | Opdivo, Opdualag, Pomalyst |
| Novartis Pharmaceuticals Corporation | $282.45 | 2022-2025 | |
| Janssen Biotech, INC. | $111.04 | 2021-2024 | Tecvayli, Imbruvica |
| Merck Sharp & Dohme LLC | $110.11 | 2021-2022 | |
| Abbvie INC. | $107.75 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $104.16 | 2021-2023 | Ultomiris |
| Celgene Corporation | $98.93 | 2021-2022 | |
| Seagen INC. | $78.47 | 2021-2023 | Tukysa |
| Morphosys, US INC. | $70.50 | 2022 | |
| Amgen INC. | $70.33 | 2021-2023 | Kyprolis, Xgeva, Vectibix |
| Rigel Pharmaceuticals, INC. | $70.09 | 2021-2022 | |
| Genzyme Corporation | $69.71 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.02 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $59.94 | 2021-2023 | Libtayo |
| Eisai INC. | $59.44 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $50.78 | 2021-2022 | |
| Epizyme, INC. | $43.55 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $38.47 | 2022-2023 | Gore Cardioform Septal Occluder |
| Daiichi Sankyo INC. | $37.97 | 2025 | Enhertu |
| Lilly USA, LLC | $33.65 | 2021 | |
| Astellas Pharma US INC | $33.47 | 2022-2023 | Padcev |
| Incyte Corporation | $32.30 | 2021-2022 | |
| Acceleron Pharma, INC. | $30.07 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $28.72 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.95 | 2021 | |
| Global Blood Therapeutics, INC. | $26.52 | 2021 | |
| Karyopharm Therapeutics INC. | $19.08 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.95 | 2022 | |
| Acrotech Biopharma INC. | $18.71 | 2023 | Beleodaq |
| Array Biopharma INC | $17.86 | 2022 | |
| Taiho Oncology, INC. | $16.86 | 2023 | |
| Myovant Sciences INC. | $15.04 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.31 | 2022 | |
| Pfizer INC. | $14.30 | 2022 | |
| Pharmacosmos Therapeutics INC. | $13.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.